Fig. 2

Prevalence of self-reported chemosensory symptoms in the acute phase (top panel) and at the follow-up (bottom panel), by the time of the acute phase and annotated with the waves and variants dominating in Europe, based on the Nextstrain prevalence data. Only groups with at least 10 patients are shown.